Patents Examined by Maher Haddad
  • Fibronectin based scaffold domain proteins that bind to myostatin
    Patent number: 8993265
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: March 31, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
  • Pharmaceutical composition for preventing or treating cancer
    Patent number: 8987425
    Abstract: The invention provides a fusion protein comprising (a) a first protein comprising a polypeptide which specifically binds to Annexin A1 and (b) a second protein comprising a polypeptide which induces a cytotoxic activity of a cytotoxic lymphocyte, pharmaceutical compositions comprising the fusion protein, and methods of treating or preventing cancer by administering the pharmaceutical compositions.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: March 24, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventor: Jae-il Lee
  • Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1)
    Patent number: 8980255
    Abstract: The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: March 17, 2015
    Assignee: Queen Mary & Westfield College
    Inventors: Mauro Perretti, Fulvio D'Acquisto, Roderick John Flower
  • Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
    Patent number: 8975029
    Abstract: The invention provides an integrin alpha-2 binding agent and methods of using an integrin alpha-2 binding agent to, e.g., inhibit proliferation of cancer cells, modulate tumor growth in a subject, inhibiting angiogenesis, or treating a fibrotic disorder. The invention further provides a method of producing an antibody, the method comprising propagating cancer cells in a 3-dimensional matrix; immunizing a mammal with the propagated cancer cells; and isolating an antibody from the immunized mammal. A method of identifying an agent that inhibits cancer cell proliferation also is provided.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 10, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Stephen J. Weiss, David T. Dudley
  • Anti-alpha2 integrin antibodies and their uses
    Patent number: 8975376
    Abstract: The invention relates to antibodies directed to ?2?1 integrin and their uses, including humanized anti-alpha 2 (?2) integrin antibodies and methods of treatment with anti-?2integrin antibodies. More specifically the present invention relates to humanized anti-?2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: March 10, 2015
    Assignee: Sanofi
    Inventors: Stanislas Blein, Samuel Hou, Darko Skegro
  • Anti-?5?1 antibodies and uses thereof
    Patent number: 8962275
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: February 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • Fibronectin based scaffold domain proteins that bind to myostatin
    Patent number: 8933199
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 13, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Martin J. Corbett, Alexander T. Kozhich
  • Fibronectin based scaffold domain proteins that bind IL-23
    Patent number: 8927693
    Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ruchira Dasgupta, Alex Bush, Lumelle Schneeweis, Linda Engle
  • Method of modulating inflammatory response by downregulation of activin
    Patent number: 8920806
    Abstract: The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and/or designing agents capable of modulating activin mediated regulation of the inflammatory response.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: December 30, 2014
    Assignee: Paranta Biosciences Limited
    Inventors: David Morritz De Kretser, David James Phillips, Kristian Lee Jones, Robyn O'Hehir, Shane Patella
  • Method for integrin ligand discovery
    Patent number: 8911952
    Abstract: This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: December 16, 2014
    Assignee: STC. UNM
    Inventors: Alexandre Chigaev, Larry A. Sklar
  • Integrin heterodimer and a subunit thereof
    Patent number: 8895253
    Abstract: A recombinant or isolated integrin heterodimer comprising a novel subunit ?10 in association with a subunit ? is described. The ?10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit of ?10 can be used as a marker or target of all types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit ?10 thereof can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: November 25, 2014
    Assignee: Xintela AB
    Inventor: Evy Lundgren-Akerlund
  • Methods for inhibiting the binding of endosialin to ligands
    Patent number: 8895000
    Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: November 25, 2014
    Assignee: Morphotek, Inc.
    Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Antagonists of activin-actriia and uses for increasing red blood cell levels
    Patent number: 8895016
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: November 25, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Antibodies directed to ?V?6 and uses thereof
    Patent number: 8894998
    Abstract: Targeted binding agents, such antibodies directed to the antigen ?V?6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen ?V?6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: November 25, 2014
    Assignee: MedImmune Limited
    Inventors: Julie Rinkenberger, Ian Foltz, Avril Alfred, Simon Thomas Barry, Vahe Bedian
  • Compositions and methods for tissue repair
    Patent number: 8889140
    Abstract: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 18, 2014
    Assignees: TransTarget, Inc., The Regents of the University of California
    Inventors: Randall J. Lee, Shirley Mihardja, Manley Huang, James W. Larrick
  • Antibodies against human tweak and uses thereof
    Patent number: 8883976
    Abstract: An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: November 11, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Hendrik Knoetgen, Jens Niewoehner
  • Detection and treatment of non-dermal fibrosis
    Patent number: 8877188
    Abstract: The invention relates to methods for the diagnosis, prognosis, and treatment of non-dermal fibrosis, including lung (or pulmonary) fibrosis.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 4, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Board of Regents, The University of Texas System
    Inventors: Sandeep K. Agarwal, Michael B. Brenner
  • Stabilized low affinity conformation of integrins for drug discovery
    Patent number: 8877893
    Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: November 4, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Timothy A. Springer, Bing Hao Luo
  • Antibodies against human tweak and uses thereof
    Patent number: 8852887
    Abstract: An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: October 7, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Hendrik Knoetgen, Jens Niewoehner
  • Humanized anti-? 9 integrin antibodies and the uses thereof
    Patent number: 8821863
    Abstract: The present invention provides humanized antibodies that immunospecifically recognize human ?9 integrin. Some of these antibodies inhibit the biological functions of the ?9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with ?9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: September 2, 2014
    Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.
    Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Shigeyuki Kon